Insperity's Earnings Bounce Looks Good-But 2026 Guidance Caps the Upside

Insperity's Q2 beat was real, but it did not settle the valuation question

Insperity posted a cleaner second quarter, yet the stock's first reaction may be overstating the fundamental upgrade.

The quarterly beat is easy to explain

Bulls can point to a straightforward beat: Insperity delivered Q2 EPS of $0.34 versus $0.32 consensus, and revenue reached $1.69 billion against $1.67 billion expected. That matters after a difficult stretch.

Bears have a reasonable counterpoint, though. In the prior quarter, Insperity had already posted $0.88 diluted EPS from continuing operations on $1.90 billion in revenue. This is less a dramatic new reversal than a business that appears to be stabilizing.

Guidance cut keeps the story tethered to execution

The bigger signal was forward-looking. Management also lowered its full-year 2026 earnings guidance and flagged higher benefits costs plus client attrition. In other words, the headline beat improves the quarter, but the lower guidance constrains the rerating case.

A bounce is understandable. A full revaluation looks harder to justify unless benefits pressure and attrition improve faster than management has currently framed.

Revenue stabilization matters, but margin follow-through is the real test

The quarter fixed the headline. The valuation fix starts now.

Revenue has stabilized; earnings quality still needs proof

Insperity has already done the easier part: stop the top-line slide. Annual revenue climbed from $4.315 billion in 2019 to $6.812 billion in 2025, and Q2 added 1.7% year-over-year revenue growth to $1.69 billion. That suggests the business is no longer losing momentum at the margin.

Still, this is not simply a return-to-growth trade. The market is also underwriting a larger earnings recovery, with earnings expected to rise from $0.99 to $1.64 per share next year. That is a much bigger leap than revenue resilience alone. It implies investors are pricing in margin improvement, not just stabilization.

The cleaner comparison is not just reported EPS. Last quarter, Insperity posted $0.88 in diluted EPS from continuing operations and said it saw early benefits from its margin recovery efforts. At the same time, management lowered its full-year 2026 earnings guidance and flagged higher benefits costs and client attrition. That is the tension investors need to watch: adjusted EPS can improve in a single quarter, but continuing-ops EPS and forward guidance matter more for judging whether the recovery is overcoming the benefits-cost and attrition drag.

What has to improve next

Revenue growth buys time. It does not automatically earn a higher multiple. From here, Insperity needs to show that each additional dollar of revenue is converting more effectively into earnings.

The main watchpoints are:

• Gross margin direction: Early margin benefits are promising, but they need follow-through, especially after guidance was lowered.
• Benefits-cost pressure: Higher healthcare and pharmacy costs still look like the main threat to near-term profitability.
• Client attrition: If client losses ease, the earnings model has a better chance of improving sustainably.

The 2029 target only matters if 2026 execution improves

The recent report gave bulls both pieces they want: a cleaner quarter and a longer-term upside model. Insperity delivered a beat, with Q2 EPS of $0.34 and revenue of $1.69 billion. Its longer-term model still points to $8.0 billion revenue and roughly $94.5 million to $104 million of earnings by 2029. The question now is whether 2026 execution can justify that path.

The stock is still being judged on proof, not potential

If you are bullish on NSP, the case is not the headline beat by itself. It is the gap between today's skepticism and a 2029 earnings picture that still implies meaningful recovery from a weak base. But that upside depends on a cleaner near-term bridge.

The company has already shown it can stabilize operations while also lowering full-year 2026 earnings guidance and flagging higher benefits costs and client attrition. That means investors still need evidence, not just narrative.

The next few quarters will decide the valuation path

Insperity has already scheduled its first quarter earnings presentation and call, and management has already provided second-quarter and full-year 2026 guidance. That creates a relatively fast feedback loop. Investors do not need to wait until 2029 to form a view.

The clearest bearish signal is simple: if benefits pressure remains sticky and 2026 guidance slips again, the longer-term 2029 targets will look more like a vision statement than a valuation anchor.